Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $10.1 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 76.71% year-over-year to $10.1 million; the TTM value through Sep 2025 reached $87.8 million, down 55.81%, while the annual FY2024 figure was $36.6 million, 36.75% down from the prior year.
  • Liabilities and Shareholders Equity reached $10.1 million in Q3 2025 per RANI's latest filing, down from $16.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $137.0 million in Q3 2021 and bottomed at $10.1 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $72.8 million, with a median of $73.9 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 56.4% in 2021, then tumbled 76.71% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $124.2 million in 2021, then decreased by 13.03% to $108.0 million in 2022, then tumbled by 46.39% to $57.9 million in 2023, then plummeted by 36.75% to $36.6 million in 2024, then crashed by 72.32% to $10.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $10.1 million in Q3 2025, $16.9 million in Q2 2025, and $24.1 million in Q1 2025.